When do the patents on JOBEVNE expire, and when will biosimilar JOBEVNE enter the market?

Last updated: September 7, 2026

JOBEVNE is the U.S. brand for bevacizumab-nwgd, a biosimilar to Roche’s Avastin. Its commercial opportunity is tied to oncology biosimilar substitution, hospital and physician purchasing, Medicare Part B reimbursement, and price competition from several established bevacizumab biosimilars. JOBEVNE has no publicly reported standalone revenue, market share, or profitability. Its financial trajectory will depend more on contracting and net price than on clinical differentiation.

What is JOBEVNE and which drug does it reference?

JOBEVNE is a biosimilar version of bevacizumab, the monoclonal antibody marketed as Avastin. Bevacizumab inhibits vascular endothelial growth factor and is used across several oncology indications, including colorectal, lung, renal, cervical, ovarian, and other cancers.

Attribute	JOBEVNE
Brand name	JOBEVNE
Active ingredient	Bevacizumab-nwgd
Reference product	Avastin
Drug class	Anti-VEGF monoclonal antibody
Regulatory pathway	U.S. biosimilar pathway under the Public Health Service Act
Primary commercial market	Oncology infusion centers, hospitals, and physician practices
Revenue disclosure	No standalone public revenue reported
Principal commercial risk	Price erosion from multiple bevacizumab biosimilars

The FDA’s biosimilar approval pathway requires a showing that the product is highly similar to the reference product and has no clinically meaningful differences in safety, purity, and potency. Approval does not automatically make a biosimilar interchangeable with its reference product. Interchangeability depends on a separate FDA determination. [1]

When did JOBEVNE enter the U.S. market?

JOBEVNE received U.S. FDA approval in 2025 as a bevacizumab biosimilar. The product entered a market that already included several FDA-approved Avastin biosimilars, reducing the opportunity for first-mover pricing and making contracting execution central to commercial performance.

The established U.S. competitive set includes:

Product	Active ingredient	Sponsor or commercial company	Market position
Avastin	Bevacizumab	Genentech/Roche	Reference product
Mvasi	Bevacizumab-awwb	Amgen	Early U.S. biosimilar entrant
Zirabev	Bevacizumab-bvzr	Pfizer	Large multinational commercial platform
Vegzelma	Bevacizumab-adcd	Celltrion	Established oncology biosimilar
Avzivi	Bevacizumab-tnjn	Bio-Thera Solutions	Competing bevacizumab biosimilar
JOBEVNE	Bevacizumab-nwgd	Commercial sponsor associated with the product	Later entrant

The number of competing products is commercially important. Payers and providers can source bevacizumab from multiple FDA-approved suppliers, limiting the ability of any one later entrant to sustain a premium price.

How large is the market for bevacizumab biosimilars?

The underlying Avastin market is large, but the addressable revenue for JOBEVNE is smaller because the market has already undergone substantial biosimilar conversion.

Bevacizumab is administered primarily by intravenous infusion. Unlike retail pharmacy products, purchasing decisions are often made by hospitals, integrated delivery networks, oncology practices, specialty distributors, and group purchasing organizations. The economic buyer may select a product based on:

acquisition cost and rebate structure;
reimbursement spread under Medicare Part B and commercial insurance;
product availability and back-order history;
vial sizes and wastage;
provider familiarity;
payer formulary placement;
manufacturer contracting support;
administration and supply-chain reliability.

The reference product’s historical sales do not translate directly into JOBEVNE revenue. Biosimilar competition generally shifts value from the originator and early entrants toward purchasers through lower prices and contracting concessions.

What is the financial trajectory for JOBEVNE?

JOBEVNE’s near-term financial trajectory is likely to follow a launch-and-share-acquisition pattern rather than a high-margin specialty-drug pattern.

Launch phase

The initial phase requires investment in:

field sales coverage for oncology accounts;
payer and provider contracting;
specialty distribution;
inventory and cold-chain logistics;
medical affairs;
pharmacovigilance;
reimbursement support;
bidding for hospital and group purchasing contracts.

Initial revenue may grow quickly if the sponsor secures a limited number of high-volume accounts. That growth does not necessarily indicate strong profitability because biosimilar contracts often include discounts, rebates, chargebacks, and administrative fees.

Share-building phase

The second phase depends on conversion from Avastin and competing biosimilars. A later entrant generally needs one of four advantages:

a lower net price;
stronger supply reliability;
preferred payer or hospital access;
a commercial partner with established oncology distribution.

Without one of these advantages, JOBEVNE may remain a secondary supplier used for portfolio diversification or price benchmarking.

Mature phase

At maturity, revenue is likely to stabilize at a lower net price than the reference product. Gross margin may remain attractive relative to many branded pharmaceutical products, but margin pressure will increase as competitors respond to contract wins.

The most relevant financial metrics are therefore:

Metric	Importance for JOBEVNE
U.S. net sales	Direct measure of commercial uptake
Biosimilar market share	Measures provider and payer adoption
Average net selling price	Shows competitive price pressure
Contract renewal rate	Indicates account durability
Gross margin	Captures manufacturing and contracting economics
Manufacturing utilization	Measures scale efficiency
Inventory turnover	Indicates supply-chain execution
SG&A per dollar of sales	Determines launch efficiency

No public filing currently establishes standalone JOBEVNE revenue, operating profit, or valuation. Any precise sales forecast would be speculative without sponsor-level reporting or syndicated market data.

What companies compete with JOBEVNE?

JOBEVNE competes against both Avastin and multiple bevacizumab biosimilars. The competitive landscape is more concentrated than in many retail generic markets because oncology biologics are purchased through institutional channels.

Amgen’s Mvasi

Mvasi was one of the earliest U.S. Avastin biosimilars and benefits from Amgen’s oncology commercial infrastructure, payer relationships, and manufacturing scale. Its early entry supports account familiarity, although early entry does not guarantee durable market share after additional competitors launch.

Pfizer’s Zirabev

Zirabev benefits from Pfizer’s global hospital and oncology presence. Pfizer can use broader contracting relationships to compete for system-level accounts. Its commercial strength may increase pricing pressure on later entrants.

Celltrion’s Vegzelma

Vegzelma adds another established supplier with a global biosimilar platform. Celltrion’s ability to bundle or coordinate oncology products may support account access.

Roche’s Avastin

Avastin retains clinical familiarity and may remain important in accounts that prioritize reference-product experience, physician preference, or established supply relationships. Its principal disadvantage is cost relative to biosimilars.

What is the FDA regulatory status of JOBEVNE?

JOBEVNE is regulated as a biosimilar rather than as a conventional small-molecule generic. Its approval supports use for the reference product’s approved indications when the FDA determines that the biosimilar meets the applicable requirements.

The key regulatory distinction is:

biosimilar approval establishes biosimilarity;
interchangeable status permits pharmacy-level substitution under applicable state law;
neither status guarantees formulary preference or commercial adoption.

The FDA Purple Book is the principal source for biologic reference-product and biosimilar information. JOBEVNE is not evaluated through the traditional generic-drug approval model under an Abbreviated New Drug Application. [2]

What is the Orange Book status of JOBEVNE?

JOBEVNE is not expected to have a conventional Orange Book listing because the Orange Book primarily covers approved drug products submitted through the drug application framework. Biologic reference products and biosimilars are tracked through the FDA’s Purple Book.

This distinction matters for patent and market-entry analysis. Generic applicants typically address Orange Book patents through Paragraph IV certifications. Biosimilar applicants follow the patent-disclosure and litigation framework established under the Biologics Price Competition and Innovation Act, commonly called the patent dance.

When does Avastin lose exclusivity, and what does that mean for JOBEVNE?

Avastin’s principal U.S. regulatory exclusivity period ended years before JOBEVNE’s approval. Avastin was approved in 2004, and the statutory 12-year reference-product exclusivity period for biologics expired in 2016. [3]

The practical barriers to JOBEVNE are therefore commercial rather than regulatory exclusivity barriers. Relevant risks include:

residual patent claims;
manufacturing know-how;
supply-chain capacity;
provider contracting;
payer coverage;
clinical-account conversion;
pricing retaliation from incumbent suppliers.

The expiration of regulatory exclusivity does not eliminate every patent issue. However, a later bevacizumab biosimilar would not face the same exclusivity barrier that delayed early biosimilar entry.

What patent litigation affects JOBEVNE?

No major publicly established patent litigation event is sufficient to support a quantified litigation adjustment to JOBEVNE’s revenue outlook. Bevacizumab biosimilar litigation has historically involved reference-product patents, manufacturing claims, licensing arrangements, and launch timing.

For JOBEVNE, the most material legal questions are:

whether the sponsor completed the statutory patent-information exchange;
whether the reference-product sponsor asserted patents;
whether the parties reached a launch or settlement agreement;
whether any settlement restricts launch timing or manufacturing;
whether later patent claims could affect supply or labeling.

A biologic biosimilar settlement can allow market entry before the expiration of every potentially relevant patent. The commercial effect depends on the specific agreement and cannot be inferred solely from FDA approval.

Are Paragraph IV challenges relevant to JOBEVNE?

Paragraph IV certification is generally associated with generic-drug applications under the Hatch-Waxman Act. It is not the standard legal mechanism for a biosimilar such as JOBEVNE.

For JOBEVNE, the relevant legal framework is the BPCIA. Biosimilar applicants may exchange patent information with the reference-product sponsor and negotiate which patents will be litigated. The absence of a Paragraph IV filing does not indicate the absence of patent risk.

What formulations and manufacturing patents protect JOBEVNE?

JOBEVNE’s commercial product is an intravenous bevacizumab formulation. The principal intellectual-property risks for a biosimilar are more likely to involve:

cell-line and expression technology;
purification processes;
viral-clearance methods;
formulation stability;
container-closure systems;
fill-finish processes;
dosing or administration methods;
manufacturing know-how.

The biosimilar sponsor’s product-specific patents, if any, are separate from the reference product’s patent estate. Public information does not establish a material JOBEVNE-specific formulation patent moat. The product’s defensibility is therefore more likely to come from regulatory approval, manufacturing scale, supply reliability, and contracts than from a broad composition-of-matter patent.

How does JOBEVNE compare with other Avastin biosimilars?

Factor	JOBEVNE	Early Avastin biosimilars
Regulatory differentiation	Limited unless interchangeability or labeling differences apply	More established regulatory history
Pricing power	Likely constrained by later entry	Greater opportunity to secure early contracts
Provider familiarity	Must be built	Existing adoption advantage
Supply-chain value	Potential differentiator	Depends on incumbent reliability
Patent barrier	Likely manageable but case-specific	Prior litigation and settlement experience
Commercial upside	Meaningful if contract-led	Higher cumulative opportunity from earlier entry
Margin outlook	Likely pressured by competition	Also subject to ongoing price erosion

JOBEVNE can still gain share if it is supplied reliably at a competitive net price. A later entrant does not need clinical superiority, but it does need a credible economic reason for providers to switch.

What generic and biosimilar launch scenarios exist for JOBEVNE?

Base-case scenario

JOBEVNE captures a modest share of U.S. bevacizumab volume through selected hospital and oncology-practice contracts. Revenue grows from a low base, while net price declines as incumbents defend share.

Upside scenario

The sponsor secures a major payer, group purchasing organization, or integrated delivery network contract. High-volume account wins accelerate utilization and improve manufacturing efficiency. Revenue growth is strong, but rebates still limit profit conversion.

Downside scenario

Established products retain preferred access, and JOBEVNE is used mainly as a secondary source. Sales remain below scale, resulting in high selling expenses per unit and weaker margins.

Geographic scenario

The United States offers the largest near-term opportunity because of high oncology spending and structured biosimilar reimbursement. European markets are more price-sensitive and may offer lower net prices. Emerging markets may provide volume but usually at materially lower price points and with greater tender exposure.

What revenue exposure does JOBEVNE create for its sponsor?

JOBEVNE’s revenue exposure is incremental rather than transformational unless the sponsor owns a broad oncology biosimilar portfolio or has a large institutional customer base.

The product can contribute:

recurring infusion-drug revenue;
manufacturing utilization;
cross-selling opportunities with other oncology products;
increased payer and hospital account access;
portfolio diversification from higher-risk pipeline assets.

Its risks include:

low net pricing;
high account-acquisition costs;
manufacturing underutilization;
delayed contract wins;
reimbursement changes;
supply interruptions;
rapid price matching by competing suppliers.

For valuation purposes, analysts should model JOBEVNE using market share, net price, and contribution margin assumptions rather than applying branded-drug peak-sales multiples.

Key Takeaways

JOBEVNE is a bevacizumab biosimilar to Avastin.
Its addressable market is established but heavily contested.
FDA approval removes the principal regulatory entry barrier, but does not guarantee interchangeability or formulary access.
Avastin’s 12-year biologic exclusivity period expired in 2016.
JOBEVNE is not expected to rely on Orange Book or Paragraph IV mechanisms.
The principal commercial levers are net price, supply reliability, payer access, and hospital contracting.
No standalone public revenue or profitability data support a precise JOBEVNE forecast.
The likely financial profile is a lower-price, volume-driven biologic business with significant contracting pressure.
Patent risk is case-specific and should be assessed through the BPCIA patent-exchange and litigation record.
JOBEVNE’s upside depends on winning institutional accounts against Mvasi, Zirabev, Vegzelma, Avzivi, and Avastin.

FAQs

Is JOBEVNE interchangeable with Avastin?

FDA biosimilar approval does not by itself establish interchangeability. Interchangeability requires a separate FDA determination and remains subject to applicable state substitution laws.

Does JOBEVNE have an Orange Book patent listing?

Biologic products such as JOBEVNE are generally tracked through the FDA Purple Book rather than the traditional Orange Book. The relevant patent process is under the BPCIA.

Who manufactures JOBEVNE?

JOBEVNE is associated with a biosimilar manufacturing and commercial platform, but sponsor-level financial disclosures do not provide sufficient standalone product economics to quantify manufacturing profitability.

Can JOBEVNE replace Avastin in oncology clinics?

Clinical use depends on FDA labeling, provider judgment, payer policy, institutional protocols, reimbursement, and supply. Biosimilar approval supports use within the approved indications but does not force automatic substitution.

What is the investment thesis for JOBEVNE?

The investment case is based on recurring oncology infusion demand and potential account wins, offset by rapid price erosion, multiple competing bevacizumab biosimilars, contracting costs, and the absence of a meaningful exclusivity moat.

References

U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable biologic products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
U.S. Food and Drug Administration. (2010). Biologics Price Competition and Innovation Act of 2009. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/biologics-price-competition-and-innovation-act-2009
Genentech, Inc. (n.d.). Avastin prescribing information. U.S. Food and Drug Administration labeling database. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Congress. (2010). Patient Protection and Affordable Care Act, Section 7002: The Biologics Price Competition and Innovation Act. https://www.congress.gov/111/plaws/publ148/PLAW-111publ148.pdf

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Summary for Tradename: JOBEVNE

Pharmacology for JOBEVNE

Note on Biologic Patents

1) High Certainty: US Patents for JOBEVNE Derived from Brand-Side Litigation

2) High Certainty: US Patents for JOBEVNE Derived from DrugPatentWatch Analysis and Company Disclosures

3) Low Certainty: US Patents for JOBEVNE Derived from Patent Text Search